{
  "abstract": "Background and Importance Ulcerative colitis (UC) can be treated with Janus kinase inhibitors (JAKi) when conventional therapies fail to control the disease. Evaluating real-world effectiveness and safety is key to improve their use.Aim and Objectives Describe and evaluate the use, effectiveness and safety of JAKi in UC in a tertiary hospital.Material and Methods Retrospective observational study involving adult UC patients with JAKi treatment during 2024 at the Pharmacy department. Patients with ≤1 year of treatment at data cut-off were excluded.Data collected: sex, age, body mass index(BMI), disease extension, prior exposure to monoclonal antibodies (mAbs), JAKi prescribed, and concomitant mAb therapy. Effectiveness was assessed by clinical (CR; Simple Clinical Colitis Activity Index(SCCAI)≤3) and biochemical remission(BR; C-reactive protein(CRP)<5mg/L and faecal calprotectin(FC)<500µg/g) at baseline and after one year. Analytical parameters (FC, CRP, transaminases, cholesterol, and haemoglobin), adverse events (AEs), and persistence were also recorded.Quantitative variables were expressed as mean±standard deviation(SD) or median/interquartile range, and qualitative variables as frequency and percentage. Wilcoxon, McNemar and Mann-Whitney U tests were applied, considering significance as p<0.05(SPSSv23).Results Forty-four patients were included, 52.3% women, mean age 27.8±1.9 years, mean BMI 24.4±0.5 kg/m2, and 65.9% presenting pancolitis. 81.8% of patients had been treated with mAbs, mainly infliximab(38.4%) and adalimumab(24.7%).Twenty-one patients received upadacitinib(47.7%), 15 tofacitinib(34.1%), and 8 filgotinib(18.2%). Thirteen patients (29,5%) received concomitant treatment with mAbs (11 from upadacitinib group).Median SCCAI at baseline and after one year of treatment was 5(4–7) and 1(0–1), respectively(p<0.001). CR increased from 18.2% (n=8) to 86.4% (n=38)(p=0.000), and BR from 18.2% (n=8) to 79.5% (n=35)(p=0.001). Upadacitinib, tofacitinib and filgotinib achieved BR of 85.7%, 86.7% and 50.0%, respectively(p=0.043).All patients had similar analytical parameters at baseline and after one year of treatment(p>0.05), except for cholesterol(p=0.023). Moreover, cholesterol values at 1 year differed between upadacitinib 228mg/dL(198–267) and tofacitinib 197mg/dL(165-233)(p=0.010), but not filgotinib 180mg/dL(168–198)(p>0.05).AEs occurred in 21 patients (47.7%), mainly dermatological(n=9), infectious (n=7) and metabolic(n=8). 95.5% of patients remained on JAKi therapy at the end of the study, with only two discontinuations due to pregnancy and malignancy.Conclusion and Relevance JAKi significantly improved CR and BR after one year, although BR was lower with filgotinib. Upadacitinib was associated with increased cholesterol values compared with tofacitinib. Despite half of patients showed AEs, treatment persistence remained high, with nearly all patients maintaining therapy.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "B Arnau Blasco"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "MJ Cuellar Monreal"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "MA Albert Mari"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "M Chovi Trull"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "D Gallen Soria"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "P Ferrando Barbera"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "I Beltran Garcia"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "P Taberner Bonastre"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Hospital Pharmacy, Valencia, Spain"
      ],
      "name": "MD Edo Solsona"
    },
    {
      "affiliations": [
        "Hospital Universitari I Politècnic La Fe, Management Department, Valencia, Spain"
      ],
      "name": "JL Poveda Andrés"
    }
  ],
  "title": "4CPS-243 Use and effectiveness of jak inhibitors in ulcerative colitis: a real-world observational analysis",
  "uid": "2cd3ed48-067d-5a7e-86de-32cc10f308fe"
}